Skip to content
Parakho

Zydus Lifesciences Ltd

NSE ZYDUSLIFEBSE 532321

Q1 FY27, unaudited

Revenue
₹8,017.00 Cr
Profit after tax
₹990.20 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations8,017.00+21.96%27,148.40
Other income106.10−31.50%509.50
Total income8,123.10+20.72%27,657.90
Employee benefit expense1,368.20+36.11%4,417.90
Finance costs156.00+84.18%438.90
Depreciation & amortisation554.70+132.97%1,408.00
Total expenses6,798.30+41.40%20,520.20
Profit before tax1,306.60−31.97%6,621.10
Tax expense354.20−18.39%1,594.70
Profit after tax990.20−34.90%5,123.50
Total comprehensive income957.70−37.24%4,348.70
Earnings per share
Earnings per share, basic₹9.35₹50.09
Earnings per share, diluted₹9.35₹50.09

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Zydus Lifesciences reported consolidated revenue of Rs. 271.5 billion for FY2025-26, growth of 17% over the previous year, with an EBITDA margin of 31.2%. Management described growth across India formulations, international markets, and Consumer Wellness, along with new entries into MedTech and biosimilars, and disclosed a post-year-end share buyback of up to Rs. 1,100 crore at Rs. 1,260 per share. Management also said the company expects high-teen revenue growth in FY27, supported by its Indian and international businesses, new product launches, and integration of recent acquisitions.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 120 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 12 Oct 2026.